Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Temozolomide in Elderly Glioblastoma
NCT04195139Phase 2Active, not recruiting
- Sponsor
- University of Sydney
- Start
- Feb 2018
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of nivolumab in glioblastoma (GBM) (2 arms), sponsored by University of Sydney. Primary endpoint: Overall Survival at 24 months. Started Feb 2018; status: active, not recruiting.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04195139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04195139.